End-to-End Services: Seamless Support from Gram Scale to Commercial Supply

JiuzhouPharma has established a full-cycle service platform covering preclinical development, Phase I–III clinical stages, and commercial manufacturing. The company can flexibly support diverse project needs ranging from milligram-scale screening and gram-scale process validation to kilogram-scale registration batches and ton-scale commercial supply. All projects operate under a unified and rigorous quality management system, ensuring smooth technology transfer and data integrity throughout the development lifecycle.

Comprehensive High-Potency Capabilities: Full OEB1–5 Coverage

To address the growing demand for high-potency compound development, JiuzhouPharma has equipped multiple manufacturing sites with fully contained production lines covering OEB1 to OEB5. These facilities enable the safe and compliant handling of compounds with varying toxicity profiles, supporting the successful advancement of highly potent projects.

Integrated API and Drug Product Services: Collaborative Development for Efficient Delivery

Supported by a unified quality system and integrated project management approach, JiuzhouPharma can efficiently connect API process development with formulation development, process scale-up, and GMP manufacturing. This integrated model helps improve project efficiency and optimize supply chain coordination. The company has successfully delivered multiple integrated API and drug product projects across therapeutic areas including diabetes, anti-inflammatory and analgesic therapies, and cardiovascular diseases.

Commercial manufacturing lines are designed and operated in compliance with GMP requirements from major regulatory authorities, including China NMPA, U.S. FDA, EU EMA, and Japan PMDA, supporting multi-region regulatory submissions.

Collaborating with Global Partners to Accelerate Innovation

During API China 2026, the JiuzhouPharma team engaged in in-depth discussions with pharmaceutical companies and academic representatives from Europe, North America, the Asia-Pacific region, and China. Key topics included high-potency compound handling, complex formulation development, and commercial manufacturing capacity strategies. JiuzhouPharma remains committed to advancing innovative therapies through strong technical platforms and robust compliance systems in collaboration with global partners.

API China 2026 will conclude on May 15. JiuzhouPharma welcomes industry partners to visit our team at the National Exhibition and Convention Center in Shanghai to discuss project opportunities and explore future collaborations together.

End-to-End Services: Seamless Support from Gram Scale to Commercial Supply

JiuzhouPharma has established a full-cycle service platform covering preclinical development, Phase I–III clinical stages, and commercial manufacturing. The company can flexibly support diverse project needs ranging from milligram-scale screening and gram-scale process validation to kilogram-scale registration batches and ton-scale commercial supply. All projects operate under a unified and rigorous quality management system, ensuring smooth technology transfer and data integrity throughout the development lifecycle.

Comprehensive High-Potency Capabilities: Full OEB1–5 Coverage

To address the growing demand for high-potency compound development, JiuzhouPharma has equipped multiple manufacturing sites with fully contained production lines covering OEB1 to OEB5. These facilities enable the safe and compliant handling of compounds with varying toxicity profiles, supporting the successful advancement of highly potent projects.

Integrated API and Drug Product Services: Collaborative Development for Efficient Delivery

Supported by a unified quality system and integrated project management approach, JiuzhouPharma can efficiently connect API process development with formulation development, process scale-up, and GMP manufacturing. This integrated model helps improve project efficiency and optimize supply chain coordination. The company has successfully delivered multiple integrated API and drug product projects across therapeutic areas including diabetes, anti-inflammatory and analgesic therapies, and cardiovascular diseases.

Commercial manufacturing lines are designed and operated in compliance with GMP requirements from major regulatory authorities, including China NMPA, U.S. FDA, EU EMA, and Japan PMDA, supporting multi-region regulatory submissions.

Collaborating with Global Partners to Accelerate Innovation

During API China 2026, the JiuzhouPharma team engaged in in-depth discussions with pharmaceutical companies and academic representatives from Europe, North America, the Asia-Pacific region, and China. Key topics included high-potency compound handling, complex formulation development, and commercial manufacturing capacity strategies. JiuzhouPharma remains committed to advancing innovative therapies through strong technical platforms and robust compliance systems in collaboration with global partners.

API China 2026 will conclude on May 15. JiuzhouPharma welcomes industry partners to visit our team at the National Exhibition and Convention Center in Shanghai to discuss project opportunities and explore future collaborations together.

End-to-End Services: Seamless Support from Gram Scale to Commercial Supply

JiuzhouPharma has established a full-cycle service platform covering preclinical development, Phase I–III clinical stages, and commercial manufacturing. The company can flexibly support diverse project needs ranging from milligram-scale screening and gram-scale process validation to kilogram-scale registration batches and ton-scale commercial supply. All projects operate under a unified and rigorous quality management system, ensuring smooth technology transfer and data integrity throughout the development lifecycle.

Comprehensive High-Potency Capabilities: Full OEB1–5 Coverage

To address the growing demand for high-potency compound development, JiuzhouPharma has equipped multiple manufacturing sites with fully contained production lines covering OEB1 to OEB5. These facilities enable the safe and compliant handling of compounds with varying toxicity profiles, supporting the successful advancement of highly potent projects.

Integrated API and Drug Product Services: Collaborative Development for Efficient Delivery

Supported by a unified quality system and integrated project management approach, JiuzhouPharma can efficiently connect API process development with formulation development, process scale-up, and GMP manufacturing. This integrated model helps improve project efficiency and optimize supply chain coordination. The company has successfully delivered multiple integrated API and drug product projects across therapeutic areas including diabetes, anti-inflammatory and analgesic therapies, and cardiovascular diseases.

Commercial manufacturing lines are designed and operated in compliance with GMP requirements from major regulatory authorities, including China NMPA, U.S. FDA, EU EMA, and Japan PMDA, supporting multi-region regulatory submissions.

Collaborating with Global Partners to Accelerate Innovation

During API China 2026, the JiuzhouPharma team engaged in in-depth discussions with pharmaceutical companies and academic representatives from Europe, North America, the Asia-Pacific region, and China. Key topics included high-potency compound handling, complex formulation development, and commercial manufacturing capacity strategies. JiuzhouPharma remains committed to advancing innovative therapies through strong technical platforms and robust compliance systems in collaboration with global partners.

API China 2026 will conclude on May 15. JiuzhouPharma welcomes industry partners to visit our team at the National Exhibition and Convention Center in Shanghai to discuss project opportunities and explore future collaborations together.